These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37365583)

  • 61. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.
    Patnaik A; Appleman LJ; Tolcher AW; Papadopoulos KP; Beeram M; Rasco DW; Weiss GJ; Sachdev JC; Chadha M; Fulk M; Ejadi S; Mountz JM; Lotze MT; Toledo FG; Chu E; Jeffers M; Peña C; Xia C; Reif S; Genvresse I; Ramanathan RK
    Ann Oncol; 2016 Oct; 27(10):1928-40. PubMed ID: 27672108
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Downregulation of p21(WAF1/CIP1) and estrogen receptor alpha in MCF-7 cells by antisense oligonucleotides containing locked nucleic acid (LNA).
    Jepsen JS; Pfundheller HM; Lykkesfeldt AE
    Oligonucleotides; 2004; 14(2):147-56. PubMed ID: 15294077
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.
    Tilly H; Morschhauser F; Bartlett NL; Mehta A; Salles G; Haioun C; Munoz J; Chen AI; Kolibaba K; Lu D; Yan M; Penuel E; Hirata J; Lee C; Sharman JP
    Lancet Oncol; 2019 Jul; 20(7):998-1010. PubMed ID: 31101489
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Inhibition of microRNA-21 via locked nucleic acid-anti-miR suppressed metastatic features of colorectal cancer cells through modulation of programmed cell death 4.
    Nedaeinia R; Sharifi M; Avan A; Kazemi M; Nabinejad A; Ferns GA; Ghayour-Mobarhan M; Salehi R
    Tumour Biol; 2017 Mar; 39(3):1010428317692261. PubMed ID: 28347230
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Demonstration of microRNA using
    Warford A; Rahman NS; Ribeiro DA; Uysal Onganer P
    Br J Biomed Sci; 2020 Jul; 77(3):135-141. PubMed ID: 32223721
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
    Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
    Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Clinical evaluation of two dosages and schedules of ifosfamide in combination with cisplatin in neo-adjuvant chemotherapy of patients with advanced (stage III-IV) head and neck squamous cell carcinoma: a phase II randomized study.
    Mantovani G; Ghiani M; Lai P; Maccio A; Dessi D; Succu G; Massa D; Curreli L; Mulas C; Esu S; Proto E; Cadeddu G; Tore G
    Oncol Rep; 1998; 5(6):1499-505. PubMed ID: 9769395
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Structure Activity Relationships of α-L-LNA Modified Phosphorothioate Gapmer Antisense Oligonucleotides in Animals.
    Seth PP; Jazayeri A; Yu J; Allerson CR; Bhat B; Swayze EE
    Mol Ther Nucleic Acids; 2012 Sep; 1(10):e47. PubMed ID: 23344239
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Targeting miR-9 in gastric cancer cells using locked nucleic acid oligonucleotides.
    Lima JF; Carvalho J; Pinto-Ribeiro I; Almeida C; Wengel J; Cerqueira L; Figueiredo C; Oliveira C; Azevedo NF
    BMC Mol Biol; 2018 Jun; 19(1):6. PubMed ID: 29879907
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors.
    Nokihara H; Yamada Y; Fujiwara Y; Yamamoto N; Wakui H; Nakamichi S; Kitazono S; Inoue K; Harada A; Taube T; Takeuchi Y; Tamura T
    Invest New Drugs; 2016 Feb; 34(1):66-74. PubMed ID: 26627079
    [TBL] [Abstract][Full Text] [Related]  

  • 72. CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.
    Sallman DA; Kerre T; Havelange V; Poiré X; Lewalle P; Wang ES; Brayer JB; Davila ML; Moors I; Machiels JP; Awada A; Alcantar-Orozco EM; Borissova R; Braun N; Dheur MS; Gilham DE; Lonez C; Lehmann FF; Flament A
    Lancet Haematol; 2023 Mar; 10(3):e191-e202. PubMed ID: 36764323
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
    Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Comparison of different chemically modified inhibitors of miR-199b in vivo.
    Duygu B; Juni R; Ottaviani L; Bitsch N; Wit JBM; de Windt LJ; da Costa Martins PA
    Biochem Pharmacol; 2019 Jan; 159():106-115. PubMed ID: 30452907
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Therapeutic efficacy of modified anti-miR21 in metastatic prostate cancer.
    Kim K; Kim HH; Lee CH; Kim S; Cheon GJ; Kang KW; Chung JK; Youn H
    Biochem Biophys Res Commun; 2020 Aug; 529(3):707-713. PubMed ID: 32736696
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Silencing of miR-21 by locked nucleic acid-lipid nanocapsule complexes sensitize human glioblastoma cells to radiation-induced cell death.
    Griveau A; Bejaud J; Anthiya S; Avril S; Autret D; Garcion E
    Int J Pharm; 2013 Oct; 454(2):765-74. PubMed ID: 23732394
    [TBL] [Abstract][Full Text] [Related]  

  • 77. First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas.
    Piha-Paul SA; Geva R; Tan TJ; Lim DW; Hierro C; Doi T; Rahma O; Lesokhin A; Luke JJ; Otero J; Nardi L; Singh A; Xyrafas A; Chen X; Mataraza J; Bedard PL
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34389618
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
    Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
    Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors.
    Heath EI; Bible K; Martell RE; Adelman DC; Lorusso PM
    Invest New Drugs; 2008 Feb; 26(1):59-65. PubMed ID: 17938863
    [TBL] [Abstract][Full Text] [Related]  

  • 80. First-in-man dose escalation and pharmacokinetic study of CAP7.1, a novel prodrug of etoposide, in adults with refractory solid tumours.
    Keilholz U; Rohde L; Mehlitz P; Knoedler M; Schmittel A; Kümmerlen V; Klinghammer K; Treasure P; Lassus M; Steventon G; Machacek M; Utku N
    Eur J Cancer; 2017 Jul; 80():14-25. PubMed ID: 28531881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.